To evaluate MYC action on RNAPII symmetrical dimethylation, we took advantage of two cancer cell types with high MYC basal levels: the glioblastoma stem cell (GSC) line named BT168 and the Burkitt’s lymphoma cell line Ramos, in which the myc gene is under control of the immunoglobulin heavy chain promoter [47,48]. This evidence concerns the gene MYC and Burkitt lymphoma.